The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody

Keywords:
Hematopoietic stem cell transplantation, Storage diseases, Hurler syndrome, Immune hemolytic anemia
1.
Drobysky WR, Potluri J, Sauer D, Gottschall JL: Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17:1093–1099.
2.
Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM, Laffan M: Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997;19:491–495.
3.
Cwynarski K, Goulding R, Pocock C, Dazzi F, Craddock C, Kaeda J, Olavarria E, Kanfer E, Apperley J, Lawler M, Goldman JM: Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: Association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant 2001;28:581–586.
4.
Coiffier B, Haioun C, Ketterer N, Egert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927–1932.
5.
McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL: Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999;24:1253–1258.
6.
Berenstein S, Tjonnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Lokkevik E, Sorbo JH, Ulvestad E: Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:79–83.
7.
Zaja F, Russo D, Fuga G, Perella G, Baccarani M: Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062–1063.
8.
Stasi R, Pagano A, Stipa E, Amadori S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952–957.
9.
Zecca M, De Stefano P, Nobili B, Locatelli F: Anti-CD20 monoclonal antibody for the treatment of severe immuno-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001;97:3995–3997.
10.
Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, De Vita S, Regazzi M, Baccarani M, Fanin R: B-cell depletion with rituximab as treatment for immune haemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189–195.
11.
Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J: Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr 2001;160:492–496.
12.
Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A: Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511–1513.
© 2003 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.